• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Intellia Therapeutics Inc.

    6/11/25 5:14:02 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NTLA alert in real time by email
    S-8 1 d42837ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 11, 2025

    Registration No. 333-

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Intellia Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-37766   36-4785571
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)
    40 Erie Street, Suite 130  
    Cambridge, Massachusetts     02139
    (Address of Principal Executive Offices)     (Zip Code)

    Intellia Therapeutics, Inc. 2025 Equity Incentive Plan

    (Full title of the plan)

    John Leonard, M.D.

    President and Chief Executive Officer

    40 Erie Street, Suite 130

    Cambridge, Massachusetts 02139

    (857) 285-6200

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Michael H. Bison, Esq.

    Gabriela Morales-Rivera, Esq.

    Goodwin Procter LLP

    100 Northern Ave.

    Boston, Massachusetts 02210

    (617) 570-1000

     

    James Basta, Esq.

    Executive Vice President, General Counsel

    Intellia Therapeutics, Inc.

    40 Erie Street, Suite 130

    Cambridge, Massachusetts 02139

    (857) 285-6200

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    On April 28, 2025, subject to stockholder approval, the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Registrant”) adopted the Intellia Therapeutics, Inc. 2025 Equity Incentive Plan (the “Plan”). The Plan was subsequently approved by the Registrant’s stockholders at the Registrant’s Annual Meeting of Stockholders held on June 11, 2025 (the “Effective Date”). The number of shares of common stock, $0.0001 par value (the “Common Stock”), authorized for issuance pursuant to the Plan is equal to (i) 5,165,178 shares of Common Stock, plus (ii) that number of shares of Common Stock remaining available for issuance as of the Effective Date under the Intellia Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the “Prior Plan”) (that is, shares not subject to outstanding awards under the Prior Plan nor delivered from the shares reserved under the Prior Plan), plus (iii) that number of shares of Common Stock subject to awards granted under the Prior Plan that are outstanding as of the Effective Date and any shares of Common Stock subject to outstanding grants under the Prior Plan that terminate, expire or are canceled, forfeited, exchanged or surrendered without having been exercised, vested or paid under the Prior Plan after the Effective Date in accordance with the provisions of the Plan (the shares in clauses (ii) and (iii), the “Prior Plan Shares”). The Registrant is filing this Registration Statement on Form S-8 (this “Registration Statement”) to register the offer and sale of an aggregate of 22,853,528 shares of Common Stock, which consists of (i) the 5,165,178 shares of Common Stock and (ii) 17,688,350 Prior Plan Shares.

    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Statement of Incorporation by Reference.

    This Registration Statement incorporates by reference the following documents, which the Registrant previously filed with the Commission:

     

      •  

    Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 27, 2025;

     

      •  

    The information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December  31, 2024 from our definitive proxy statement on Schedule 14A (other than information furnished rather than filed), which was filed with the Commission on April 30, 2025;

     

      •  

    Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 8, 2025;

     

      •  

    Current Reports on Form 8-K, filed with the Commission on January 10, 2025, February  21, 2025, February  27, 2025, April  7, 2025, May  19, 2025, and May 28, 2025; and

     

      •  

    The description of our Common Stock contained in our registration statement on Form 8-A filed with the Commission on May 5, 2016 under Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description.


    In addition, all reports and other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment hereto, which indicates that all securities offered have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

    The Registrant has adopted provisions in the Registrant’s certificate of incorporation and by-laws that limit or eliminate the personal liability of the Registrant’s directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director or officer will not be personally liable to the Registrant or its stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability in limited circumstances.

    These limitations of liability do not alter director or officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

    In addition, the Registrant’s by-laws provide that:

     

      •  

    the Registrant will indemnify its directors, officers and, in the discretion of its board of directors, certain employees and agents to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

     

      •  

    the Registrant will advance reasonable expenses, including attorneys’ fees, to its directors and, in the discretion of its board of directors, to its officers and certain employees and agents, in connection with legal proceedings relating to their service for or on behalf of the Registrant, subject to limited exceptions.

    The Registrant has entered into indemnification agreements with each of its directors and officers. These agreements provide that the Registrant will indemnify each of its directors, executive officers, certain other officers and, at times, their affiliates, to the fullest extent permitted by the DGCL.


    The Registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    See the Exhibit Index below for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    EXHIBIT INDEX

     

    Number   

    Description

    4.1    Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on May 17, 2016)
    4.2    Second Amended and Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of the Registrant’s Annual Report on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 27, 2025)
    4.3    Third Amended and Restated By-Laws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on April 7, 2025)
    5.1*    Opinion of Goodwin Procter LLP
    23.1*    Consent of Goodwin Procter LLP (included in Exhibit 5.1)
    23.2*    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    24.1*    Power of attorney (included on the signature pages of this registration statement)
    99.1*    Intellia Therapeutics, Inc. 2025 Equity Incentive Plan
    107.1*    Filing Fee Table
     
    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 11th day of June, 2025.

     

    INTELLIA THERAPEUTICS, INC.
    By:  

    /s/ John Leonard

      John Leonard, M.D.
      President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of John Leonard, M.D., James Basta, J.D. and Edward Dulac as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.


    Name

      

    Title

      

    Date

    /s/ John M. Leonard

       President, Chief Executive Officer and Director    June 11, 2025
    John M. Leonard, M.D.    (Principal Executive Officer)   

    /s/ Edward J. Dulac III

       Executive Vice President, Chief Financial Officer    June 11, 2025
    Edward J. Dulac III    (Principal Financial Officer)   

    /s/ Michael P. Dube

       Vice President, Chief Accounting Officer    June 11, 2025
    Michael P. Dube    (Principal Accounting Officer)   

    /s/ Muna Bhanji

       Director    June 11, 2025
    Muna Bhanji      

    /s/ Bill Chase

       Director    June 11, 2025
    Bill Chase      

    /s/ Fred Cohen

       Director    June 11, 2025
    Fred Cohen, M.D.      

    /s/ Brian Goff

       Director    June 11, 2025
    Brian Goff      

    /s/ Jesse Goodman

       Director    June 11, 2025
    Jesse Goodman, M.D.      

    /s/ Georgia Keresty

       Director    June 11, 2025
    Georgia Keresty      

    /s/ Frank Verwiel

       Director    June 11, 2025
    Frank Verwiel, M.D.      
    Get the next $NTLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTLA

    DatePrice TargetRatingAnalyst
    4/21/2025$21.00Peer Perform → Outperform
    Wolfe Research
    3/5/2025$30.00Buy
    H.C. Wainwright
    2/28/2025$45.00 → $13.00Overweight → Neutral
    Analyst
    2/28/2025$9.00Neutral → Sell
    Goldman
    1/27/2025$56.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    2/23/2024$136.00 → $32.00Buy → Neutral
    Goldman
    2/15/2024Peer Perform
    Wolfe Research
    4/13/2023$66.00Buy
    Canaccord Genuity
    More analyst ratings

    $NTLA
    SEC Filings

    See more
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      6/12/25 4:31:54 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Intellia Therapeutics Inc.

      S-8 - Intellia Therapeutics, Inc. (0001652130) (Filer)

      6/11/25 5:14:02 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      5/28/25 4:38:43 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

      Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

      11/16/24 10:16:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

      Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do

      10/24/24 8:01:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

      - Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A

      10/10/24 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units ("RSUs") for 33,600 shares of Intellia's common stock, with one-third of such RSUs vesting on June 1, 2026, 2027 and 2028. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Intellia throug

      6/5/25 4:01:00 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

      Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were previously progressing on patisiranContinue to observe generally favorable safety and tolerability data in the full Phase 1 cohort with no new drug-related adverse events within the follow-up periodEnrollment continues to progress well in MAGNITUDE-2, which is designed to measure clinical outcomes (including mNIS+7) and evaluate how a single dose of nex-z can lead to reduction in serum TTR, to potentially support a BLA submission by 2028 CAMBRIDG

      5/18/25 7:25:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

      On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z

      5/8/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NTLA
    Financials

    Live finance-specific insights

    See more

    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

      On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z

      5/8/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available throug

      5/1/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

      Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year endActively screening for the Phase 3 MAGNITUDE-2 trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy; on track to dose first patient in 1Q25En

      2/27/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Bhanji Muna sold $2,252 worth of shares (265 units at $8.50), decreasing direct ownership by 1% to 19,203 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      5/1/25 4:24:22 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • EVP, Chief Technical Officer Clark Eliana was granted 32,000 shares and sold $6,104 worth of shares (679 units at $8.99), increasing direct ownership by 49% to 95,369 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      3/4/25 4:43:16 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • President and CEO Leonard John M was granted 136,000 shares, increasing direct ownership by 14% to 1,077,115 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      3/4/25 4:41:19 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

      SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

      2/13/24 5:07:59 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

      SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

      1/29/24 4:00:59 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

      SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

      1/24/24 11:21:06 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Intellia Therapeutics from Peer Perform to Outperform and set a new price target of $21.00

      4/21/25 8:30:53 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • H.C. Wainwright initiated coverage on Intellia Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $30.00

      3/5/25 7:39:47 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics downgraded by Analyst with a new price target

      Analyst downgraded Intellia Therapeutics from Overweight to Neutral and set a new price target of $13.00 from $45.00 previously

      2/28/25 7:27:33 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care